News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
New Alzheimer's Association Report: Americans Care Deeply About Brain Health But Most Don't Know How to Maintain It
The 2026 Facts and Figures report found 7.4 million Americans living with clinical Alzheimer's dementia, $409 billion in projected 2026 care costs, and a 134% rise in Alzheimer's-related deaths since 2000, alongside survey findings that most Americans don't know concrete steps to protect brain health (only 14% had discussed it with a doctor).
Why it matters: Updates the national scale and cost of Alzheimer's disease for policymakers and funders, and highlights a public-education gap around modifiable brain-health behaviors like sleep, diet, and exercise.
Read at Alzheimer's Association → Archived copy (26 Jul 2026), Internet Archive$100 Million Increase for Alzheimer's and Dementia Research Signed Into Law
The FY2026 federal spending package signed into law includes a $100 million increase for Alzheimer's and dementia research at NIH, bringing total funding to about $3.9 billion, plus $41.5 million for the CDC's BOLD Infrastructure for Alzheimer's Act, the highest level since that law's enactment.
Why it matters: Converts the earlier Senate committee proposal into enacted law, securing real funding increases for research and public-health infrastructure despite a contentious broader budget environment.
Read at Alzheimer's Association → Archived copy (25 Aug 2026), Internet ArchiveAlzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in more than 3,800 people with early symptomatic Alzheimer's did not meet the primary endpoint of significantly slowing disease progression, despite improving some Alzheimer's-related biomarkers. Novo Nordisk ended its Alzheimer's trials for semaglutide, including the injectable version.
Why it matters: A high-profile failure for the theory that GLP-1 weight-loss drugs could treat Alzheimer's, dampening near-term hopes for repurposing this popular drug class for dementia.
Read at Alzheimer's Association → Archived copy (30 Jul 2026), Internet ArchiveHouse Introduces Bipartisan Legislation to Accelerate Access to Alzheimer's Screening (ASAP Act)
Reps. Vern Buchanan (R-FL) and Paul Tonko (D-NY) introduced the Alzheimer's Screening and Prevention (ASAP) Act, which would create a Medicare coverage pathway for FDA-approved blood-based dementia screening tests.
Why it matters: Targets a gap identified by clinicians and advocates: despite new FDA-cleared blood tests, Medicare currently won't pay for them as a pre-symptomatic screening tool.
Read at Alzheimer's Association → Archived copy (7 Aug 2026), Internet ArchiveFDA Approves Weekly Subcutaneous Maintenance Dosing for Leqembi (Leqembi IQLIK)
The FDA approved a weekly at-home subcutaneous autoinjector maintenance dose of lecanemab (Leqembi IQLIK) for early Alzheimer's disease, the first amyloid-clearing antibody approved for self- or caregiver-administered injection. Patients who complete the initial 18-month IV infusion phase can switch to weekly injections.
Why it matters: Reduces the burden of regular infusion-center visits for patients and caregivers, making long-term treatment more convenient and potentially improving adherence.
Read at Alzheimer's Association → Archived copy (8 Jun 2026), Internet ArchiveSenate Appropriations Committee Approves $100 Million Increase for Alzheimer's Research
The Senate Appropriations Committee approved a $100 million increase in NIH funding for Alzheimer's and dementia research for FY2026, which would bring total annual federal funding to about $3.9 billion, plus $41.5 million for CDC's Healthy Brain Initiative/BOLD Act programs.
Why it matters: Signals continued bipartisan congressional support for dementia research funding even amid broader proposed NIH budget cuts in the administration's FY2026 request.
Read at Alzheimer's Association → Archived copy (21 May 2026), Internet ArchiveAlzheimer's Association Center for Dementia Respite Innovation Awards More Than $4 Million in New Round of Grants
The Alzheimer's Association's Center for Dementia Respite Innovation awarded over $4 million to 41 community-based providers in 26 states, the second year of a five-year, $25 million program funded by a federal Administration for Community Living grant, to expand dementia-specific respite care.
Why it matters: Directly funds more respite care options for the nearly 12 million unpaid dementia caregivers nationwide, addressing one of caregivers' most requested forms of support.
Read at Alzheimer's Association → Archived copy (12 Apr 2026), Internet Archive2025 Alzheimer's Disease Facts and Figures Report
The Alzheimer's Association's annual report found 7.2 million Americans 65+ living with Alzheimer's, nearly 12 million family caregivers providing 19.2 billion hours of unpaid care (valued at about $413 billion), and total 2025 care costs projected at $384 billion; nearly 4 in 5 Americans said they'd want to know if they had Alzheimer's before symptoms worsened.
Why it matters: The most-cited annual benchmark data for the scale of Alzheimer's disease and its caregiving burden in the U.S., used by policymakers and advocates to justify funding and support programs.
Read at Alzheimer's Association → Archived copy (16 Feb 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.